AU2019344922B2 - O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors - Google Patents

O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors Download PDF

Info

Publication number
AU2019344922B2
AU2019344922B2 AU2019344922A AU2019344922A AU2019344922B2 AU 2019344922 B2 AU2019344922 B2 AU 2019344922B2 AU 2019344922 A AU2019344922 A AU 2019344922A AU 2019344922 A AU2019344922 A AU 2019344922A AU 2019344922 B2 AU2019344922 B2 AU 2019344922B2
Authority
AU
Australia
Prior art keywords
methyl
acetamide
oxy
thiazol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019344922A
Other languages
English (en)
Other versions
AU2019344922A1 (en
Inventor
Nathan GENUNG
Ryan GIANATASSIO
Kevin M. Guckian
Edward Yin Shiang LIN
Jeffrey Vessels
Zhili Xin
Lei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2019344922A1 publication Critical patent/AU2019344922A1/en
Application granted granted Critical
Publication of AU2019344922B2 publication Critical patent/AU2019344922B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AU2019344922A 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors Active AU2019344922B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US62/733,484 2018-09-19
US201862750000P 2018-10-24 2018-10-24
US62/750,000 2018-10-24
PCT/US2019/051661 WO2020061150A1 (en) 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Publications (2)

Publication Number Publication Date
AU2019344922A1 AU2019344922A1 (en) 2021-03-25
AU2019344922B2 true AU2019344922B2 (en) 2025-02-06

Family

ID=68073263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019344922A Active AU2019344922B2 (en) 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Country Status (22)

Country Link
US (2) US12180205B2 (https=)
EP (1) EP3853226A1 (https=)
JP (2) JP7606960B2 (https=)
KR (1) KR20210060513A (https=)
CN (2) CN113166137B (https=)
AU (1) AU2019344922B2 (https=)
BR (1) BR112021004739A2 (https=)
CA (1) CA3113009A1 (https=)
CL (1) CL2021000646A1 (https=)
CO (1) CO2021004873A2 (https=)
CR (1) CR20210181A (https=)
IL (2) IL315564A (https=)
JO (1) JOP20210036A1 (https=)
MA (1) MA53648A (https=)
MX (1) MX2021003232A (https=)
PE (1) PE20211591A1 (https=)
PH (1) PH12021550439A1 (https=)
SG (1) SG11202102379XA (https=)
TW (1) TWI863926B (https=)
UA (1) UA130690C2 (https=)
UY (1) UY38376A (https=)
WO (1) WO2020061150A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180205B2 (en) * 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
WO2022031701A1 (en) * 2020-08-03 2022-02-10 Biogen Ma Inc. Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease
US12612396B1 (en) 2024-11-20 2026-04-28 Dewpoint Therapeutics, Inc. Modulators of beta catenin and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109202A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
WO2013170072A2 (en) 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
PT2970272T (pt) 2013-03-14 2019-06-05 Merck Patent Gmbh Inibidores de glicosidase
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR20160100408A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
US20190359609A1 (en) * 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
JP7453916B2 (ja) * 2018-03-14 2024-03-21 バイオジェン・エムエイ・インコーポレイテッド Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グリコピラノシダーゼ阻害剤
US11459324B2 (en) 2018-03-14 2022-10-04 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
CA3102903A1 (en) 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
US12180205B2 (en) 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109202A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
SG11202102379XA (en) 2021-04-29
US20240308995A1 (en) 2024-09-19
IL281514B2 (en) 2025-02-01
IL281514A (en) 2021-04-29
JP2022500472A (ja) 2022-01-04
UY38376A (es) 2020-04-30
AU2019344922A1 (en) 2021-03-25
CO2021004873A2 (es) 2021-07-30
BR112021004739A2 (pt) 2021-06-01
CN119219621A (zh) 2024-12-31
JP2025011144A (ja) 2025-01-23
TWI863926B (zh) 2024-12-01
US12275728B2 (en) 2025-04-15
UA130690C2 (uk) 2026-04-22
PH12021550439A1 (en) 2021-11-29
CN113166137B (zh) 2024-08-16
CN113166137A (zh) 2021-07-23
WO2020061150A1 (en) 2020-03-26
TW202031651A (zh) 2020-09-01
EP3853226A1 (en) 2021-07-28
JOP20210036A1 (ar) 2021-02-25
CL2021000646A1 (es) 2021-09-03
US20220041586A1 (en) 2022-02-10
IL281514B1 (en) 2024-10-01
IL315564A (en) 2024-11-01
CA3113009A1 (en) 2020-03-26
CR20210181A (es) 2021-07-01
US12180205B2 (en) 2024-12-31
JP7606960B2 (ja) 2024-12-26
KR20210060513A (ko) 2021-05-26
PE20211591A1 (es) 2021-08-18
MA53648A (fr) 2021-07-28
MX2021003232A (es) 2021-07-16

Similar Documents

Publication Publication Date Title
AU2019344922B2 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
JP2025504486A (ja) Ｋｒａｓの標的分解のための化合物及び方法
CA2961607C (en) Mk2 inhibitors and uses thereof
AU2014261894C1 (en) Biheteroaryl compounds and uses thereof
EA037942B1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, неврологии и иммунологии
JP2019523266A (ja) 医薬化合物
AU2020421426A1 (en) RORγt inhibitor, preparation method thereof and use thereof
CA3226796A1 (en) Novel parp7 inhibitor and use thereof
JP7213193B2 (ja) Ｎｉｋ阻害剤としての新規の置換アザインドリン誘導体
KR102920418B1 (ko) 키나아제 억제 활성을 갖는 화합물
AU2022271927B2 (en) Compound having anti-tumor activity and use thereof
WO2020011147A1 (en) RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE
WO2022200523A9 (en) Pharmaceutical compounds as inhibitors of ubiquitin specific protease 19 (usp19)
US12545682B2 (en) Heterocyclic derivatives as P2X7 receptor antagonists
AU2020421654A1 (en) RORγt inhibitor, preparation method thereof and use thereof
WO2024233639A2 (en) Stat degraders and uses thereof
EA048485B1 (ru) Гетероциклические производные в качестве антагонистов рецептора p2x7

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)